With the implementation of the CETA, as of September 21, 2017, Canadian law now provides for certificates of supplementary protection that extend the term of
certain pharmaceutical patents for up to two years.
Not exact matches
• improving the right of
pharmaceutical companies to appeal a loss in
certain specialized
pharmaceutical patent litigation cases called «NOC proceedings.»
In parallel with the consultation on the
Patent Rules, the CETA Implementation Act will also affect patents by introducing patent term extensions through certificates of supplementary protection (CSPs) for certain pharmaceutical inventions, and an overhauled the patent linkage s
Patent Rules, the CETA Implementation Act will also affect
patents by introducing
patent term extensions through certificates of supplementary protection (CSPs) for certain pharmaceutical inventions, and an overhauled the patent linkage s
patent term extensions through certificates of supplementary protection (CSPs) for
certain pharmaceutical inventions, and an overhauled the
patent linkage s
patent linkage system.
The defensive protection is less controversial, where advocates of traditional knowledge protection are trying to stop people from acquiring IP rights over traditional knowledge — for example, if a
pharmaceutical company goes into an indigenous community, learns about the use of a
certain plant for treatment of disease, does a little more research, and then
patents the knowledge.